CMG Pharmaceutical Co., Ltd. (058820.KQ)
KRW 2470.0
(0.2%)
KRW 2470.0
(0.2%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 19.06 Billion KRW | 300.1% |
| 2022 | 4.76 Billion KRW | 44.32% |
| 2021 | 3.3 Billion KRW | 11.83% |
| 2020 | 2.95 Billion KRW | 0.0% |
| 2019 | - KRW | 0.0% |
| 2018 | - KRW | 0.0% |
| 2017 | - KRW | 0.0% |
| 2016 | - KRW | 0.0% |
| 2015 | - KRW | 0.0% |
| 2014 | - KRW | -100.0% |
| 2013 | 1.34 Billion KRW | 0.0% |
| 2012 | - KRW | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q2 | 18.28 Billion KRW | 30.31% |
| 2024 Q1 | 19.35 Billion KRW | 1.55% |
| 2023 Q3 | 18.02 Billion KRW | -1.25% |
| 2023 Q4 | 19.06 Billion KRW | 5.78% |
| 2023 FY | 25.03 Billion KRW | 293.82% |
| 2023 Q1 | 15.55 Billion KRW | 226.5% |
| 2023 Q2 | 18.24 Billion KRW | 17.31% |
| 2022 Q3 | 3.49 Billion KRW | 3.06% |
| 2022 Q2 | 3.39 Billion KRW | 1.86% |
| 2022 Q1 | 3.33 Billion KRW | 0.9% |
| 2022 Q4 | 4.76 Billion KRW | 36.25% |
| 2022 FY | 6.35 Billion USD | 6387.68% |
| 2021 Q3 | 3.27 Billion KRW | 4.48% |
| 2021 FY | 97.97 Million USD | 41.62% |
| 2021 Q2 | 3.13 Billion KRW | 3.1% |
| 2021 Q4 | 3.3 Billion KRW | 0.82% |
| 2021 Q1 | 3.04 Billion KRW | 2.98% |
| 2020 Q4 | 2.95 Billion KRW | 2.12% |
| 2020 FY | 69.18 Million USD | -49.01% |
| 2020 Q1 | - KRW | 0.0% |
| 2020 Q2 | 2.8 Billion KRW | 0.0% |
| 2020 Q3 | 2.89 Billion KRW | 2.92% |
| 2019 Q2 | - KRW | 0.0% |
| 2019 Q1 | - KRW | 0.0% |
| 2019 Q4 | - KRW | 0.0% |
| 2019 FY | 2.67 Billion USD | 0.0% |
| 2019 Q3 | - KRW | 0.0% |
| 2018 Q3 | - KRW | 0.0% |
| 2018 FY | - USD | 0.0% |
| 2018 Q4 | - KRW | 0.0% |
| 2018 Q2 | - KRW | 0.0% |
| 2018 Q1 | - KRW | 0.0% |
| 2017 Q4 | - KRW | 0.0% |
| 2017 FY | - USD | 0.0% |
| 2017 Q1 | - KRW | 0.0% |
| 2017 Q2 | - KRW | 0.0% |
| 2017 Q3 | - KRW | 0.0% |
| 2016 Q4 | - KRW | 0.0% |
| 2016 Q2 | - KRW | 0.0% |
| 2016 Q1 | - KRW | 0.0% |
| 2016 Q3 | - KRW | 0.0% |
| 2016 FY | - USD | -100.0% |
| 2015 Q1 | - KRW | 0.0% |
| 2015 Q4 | - KRW | 0.0% |
| 2015 FY | 3.06 Million USD | 0.0% |
| 2015 Q3 | - KRW | 0.0% |
| 2015 Q2 | - KRW | 0.0% |
| 2014 Q3 | 1.42 Billion KRW | -2.41% |
| 2014 Q1 | 1.35 Billion KRW | 1.44% |
| 2014 FY | - USD | 0.0% |
| 2014 Q4 | - KRW | -100.0% |
| 2014 Q2 | 1.45 Billion KRW | 7.2% |
| 2013 FY | - USD | 0.0% |
| 2013 Q1 | 15.93 Billion KRW | 0.0% |
| 2013 Q2 | - KRW | -100.0% |
| 2013 Q3 | 1.37 Billion KRW | 0.0% |
| 2013 Q4 | 1.34 Billion KRW | -2.4% |
| 2012 Q4 | - KRW | 0.0% |
| 2012 FY | - USD | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| HLB Pharmaceutical Co., Ltd | 988.75 Million KRW | -1828.078% |
| Celltrion Pharm, Inc. | 4.33 Billion KRW | -339.94% |
| Huons Global Co., Ltd. | 66.94 Billion KRW | 71.522% |
| DongKook Pharmaceutical Co., Ltd. | 18.74 Billion KRW | -1.675% |
| Enzychem Lifesciences Corporation | 1.02 Billion KRW | -1759.902% |
| Humedix Co., Ltd. | 1.75 Billion KRW | -986.064% |
| Boditech Med Inc. | 2.09 Billion KRW | -807.835% |
| EuBiologics Co., Ltd. | 2.8 Billion KRW | -580.857% |
| FutureChem Co.,Ltd | 2.61 Billion KRW | -627.69% |
| Huons Co., Ltd. | 58.35 Billion KRW | 67.328% |
| BNC Korea Co., Ltd. | 301.69 Million KRW | -6219.062% |
| AptaBio Therapeutics Inc. | 13.56 Billion KRW | -40.492% |